Inadequate Clinical Response to Sirukumab, an Anti-IL-6 Monoclonal Antibody, Can be Predicted after a Single Dose of Treatment in Patients with Rheumatoid Arthritis

被引：0

作者：

Daga, Shruti ^{[1
]}

Aletaha, Daniel ^{[2
]}

Hsu, Benjamin ^{[3
]}

Gilbride, Jennifer ^{[4
]}

Christie, Jacquie ^{[5
]}

Loza, Matthew ^{[3
]}

Dasgupta, Bidisha ^{[3
]}

Campbell, Kim ^{[3
]}

Brown, Kurt ^{[6
]}

Rao, Ravi ^{[5
]}

Tak, Paul P. ^{[5
]}

机构：

[1] GlaxoSmithKline, Uxbridge, Middx, England

[2] Med Univ Vienna, Div Rheumatol, Dept Med 3, Vienna, Austria

[3] Janssen Res & Dev LLC, Spring House, PA USA

[4] Sum Sq Ltd, Walkern, Herts, England

[5] GlaxoSmithKline, Stevenage, Herts, England

[6] GlaxoSmithKline, Collegeville, PA USA

来源：

ARTHRITIS & RHEUMATOLOGY | 2017年 / 69卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1478

引用

页数：3

共 50 条

[41] Anti-IL-6 monoclonal antibody (BE-8) and suramin for treatment of Castleman's disease (CD)
Munshi, NC
Wijdenes, J
Fassas, A
Vesole, D
Jagannath, SJ
Cheson, B
Butch, A
Dhodapkar, M
Tricot, G
Barlogie, B
BLOOD, 1995, 86 (10) : 745 - 745
[42] How does anti-IL-6 receptor monoclonal antibody tocilizumab treatment ameliorate neuromyelitis optica?
Matsuoka, T.
Araki, M.
Yamaguchi, H.
Sato, W.
Miyamoto, K.
Kusunoki, S.
Gold, R.
Yamamura, T.
MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 1000 - 1001
[43] BENEFICIAL EFFECT OF ANTI-IL-6 BLOCKADE ON INSULIN RESISTANCE AND INSULIN SENSITIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS
Remuzgo-Martinez, S.
Lopez-Mejias, R.
Genre, F.
Mijares, V.
Calvo-Alen, J.
Blanco, R.
Llorca, J.
Castaneda, S.
Gonzalez-Gay, M. A.
ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 330 - 330
[44] Reduction of serum matrix metalloproteinase-3 in rheumatoid arthritis patients following anti-IL-6 receptor antibody therapy.
Nishimoto, N
Okada, Y
Obata, KI
Matsumoto, T
Nakahara, H
Kishimoto, T
Yoshizaki, K
ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S83 - S83
[45] Efficacy and safety of tocilizumab, an anti-IL-6 receptor monoclonal antibody; in patients with polyarticular or oligoarticular onset juvenile idiopathic arthritis.
Imagawa, Tomoyuki
Mori, Masaaki
Takei, Syuji
Kawano, Yoshifumi
Iwata, Naomi
Miyoshi, Mari
Murata, Takuji
Nishimoto, Norihiro
Kishimoto, Tadamitsu
Yokota, Shumpei
ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S168 - S168
[46] Role of adiponectin in non-diabetic patients with rheumatoid arthritis undergoing anti-IL-6 therapy
Pulito-Cueto, V
Remuzgo-Martinez, S.
Genre, F.
Calvo-Alen, J.
Aurrecoechea, E.
Llorente, I
Triguero-Martinez, A.
Blanco, R.
Llorca, J.
Ruiz-Lucea, E.
Rivera Garcia, N.
Gualillo, O.
Lopez-Mejias, R.
Castaneda, S.
Gonzalez-Gay, M. A.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2022, 40 (05) : 988 - 992
[47] WORK PRODUCTIVITY/INTERFERENCE AND GENERAL HEALTH STATUS IMPROVEMENTS WITH SIRUKUMAB, AN ANTI-IL-6 CYTOKINE MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE TREATMENT WITH DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS: RESULTS FROM THE PHASE 3 SIRROUND-D STUDY
Takeuchi, T.
Karpouzas, G.
Thorne, C.
McQuarrie, K.
Sheng, S.
Xu, W.
Peterson, S.
Ganguly, R.
Han, C.
Fei, K.
Hsu, B.
VALUE IN HEALTH, 2016, 19 (07) : A542 - A542
[48] Consistent clinical response resulted from three Japanese randomized controlled trials of tocilizumab, humanized anti-IL-6 receptor antibody, in active rheumatoid arthritis (RA) patients.
Nishimoto, Norihiro
Miyasaka, Nobuyuki
Yamamoto, Kazuhiko
Kawai, Shinichi
Takeuchi, Tsutomu
Azuma, Junichi
Kishimoto, Tadamitsu
ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S410 - S410
[49] SARILUMAB Human anti-CD126 (IL-6R) monoclonal antibody Treatment of rheumatoid arthritis
Cole, P.
DRUGS OF THE FUTURE, 2014, 39 (05) : 339 - 343
[50] Evaluation of anti-IL-6 monoclonal antibody therapy using murine type II collagen-induced arthritis
Bailin Liang
Zheng Song
Bin Wu
Debra Gardner
David Shealy
Xiao-Yu Song
Paul H Wooley
Journal of Inflammation, 6

← 1 2 3 4 5 →